Thermo Fisher Scientific Inc. (NYSE:TMO) faces investor focus on pharma/biotech spending, revenue from deals like Clario, progress on the microbiology divestiture, new products, AI and global expansion even as it scrambles to patch a high‑severity flaw in its DNA analysis software—adding digital si…
Explore more price target data and ratings for Thermo Fisher Scientific Inc on the Forecasts tab, and track all previous and future analyst recommendations for Thermo Fisher Scientific Inc in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research System…
What Happened? Shares of life sciences company Thermo Fisher NYSE:TMOjumped 9.7% in the afternoon session after the company reported strong second-quarter earnings that beat Wall Street's estimates for both profit and revenue. For the quarter, the company reported adjusted earnings per share of $6…
Q2 delivered double-digit revenue and EPS growth, with strong performance across all segments and geographies. Full-year guidance was raised for both revenue and EPS, reflecting robust customer activity, successful acquisitions, and continued innovation.Based on Thermo Fisher Scientific Inc [TMO] Q…
Life sciences company Thermo Fisher NYSE:TMO announced better-than-expected revenue in Q2 CY2026, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.Thermo Fisher (TMO) Q2 CY2026 Highlights:Company OverviewWith ove…
RNS Number : 2794N Immupharma PLC 22 July 2026 This announcement contains inside information for the purposes of the UK Market Abuse Regulations ('UK MAR'). Upon publication of this announcement, this inside information (as defined in UK MAR) is now considered to be in the public domain. The pe…
WALTHAM, Mass.--(BUSINESS WIRE)--July 01, 2026--Thermo Fisher Scientific Inc. NYSE:TMO, the world leader in serving science, announced that it will release its financial results for the second quarter 2026 before the market opens on Thursday, July 23, 2026, and will hold a conference call on the sa…
RNS Number : 0755K Genedrive PLC 29 June 2026 29 June 2026genedrive plc("genedrive" or the "Company")CYP2C19 Product Development Collaboration agreement with Thermo Fisher Scientific Inc.genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce a collab…
